Literature DB >> 23567262

The regulation of the UCH-L1 gene by transcription factor NF-κB in podocytes.

Hongxia Zhang1, Yu Sun, Ruimin Hu, Weili Luo, Xing Mao, Zhonghua Zhao, Qi Chen, Zhigang Zhang.   

Abstract

In kidney, the ubiquitin carboxy-terminal hydrolase 1 (UCH-L1) is involved in podocyte injury and proteinuria but details of the mechanism underlying its regulation are not known. Activation of NF-κB is thought to be the predominant risk factor for kidney disease; therefore, it is postulated that UCH-L1 may be one of the NF-κB target genes. In this study, we investigated the involvement of NF-κB activation in the regulation of UCH-L1 expression and the function of murine podocytes. Stimulation of podocytes with the cytokines TNF-α and IL-1β up-regulated UCH-L1 expression rapidly at the mRNA and protein levels and the NF-κB-specific inhibitor pyrrolidine dithiocarbamate resulted in down-regulation. NF-κB up-regulates UCH-L1 via binding the --300 bp and --109 bp sites of its promoter, which was confirmed by the electrophoretic mobility shift assay of DNA-nuclear protein binding. In the renal biopsy from lupus nephritis patients, the expressions of NF-κB and UCH-L1 increased in immunohistochestry staining and were positively correlated. Activation of NF-κB up-regulates UCH-L1 expression following changing of other podocytes molecules, such as nephrin and snail. These results suggest that activation of the NF-κB signaling pathway could be the major pathogenesis to up-regulate UCH-L1 in podocyte injury, followed by the turnover of other molecules, which might result in morphological changes and dysfunction of podocytes. This work help us to understand the effect of NF-κB on specific target molecules of podocytes, and suggest that targeting the NF-κB-UCH-L1 interaction could be a novel therapeutic strategy for the treatment of podocyte lesions and proteinuria.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23567262     DOI: 10.1016/j.cellsig.2013.03.018

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

1.  UCH-L1 in DLBCL: marker or target?

Authors:  Joseph S Pagano; Julia Shackelford
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

2.  Role of A20/TNFAIP3 deficiency in lupus nephritis in MRL/lpr mice.

Authors:  Ling Sun; Lu-Xi Zou; Yu-Chen Han; Dong-Dong Zhu; Ting Chen; Jie Wang
Journal:  Clin Exp Nephrol       Date:  2019-12-07       Impact factor: 2.801

Review 3.  UCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?

Authors:  Ji-Hong Cui; Xin Xie
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

4.  Inhibition of spinal UCHL1 attenuates pain facilitation in a cancer-induced bone pain model by inhibiting ubiquitin and glial activation.

Authors:  Wei Cheng; Yuan-Li Chen; Liang Wu; Bei Miao; Qin Yin; Jin-Feng Wang; Zhi-Jian Fu
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 5.  Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy.

Authors:  Haoran Dai; Qingquan Liu; Baoli Liu
Journal:  J Diabetes Res       Date:  2017-07-16       Impact factor: 4.011

Review 6.  NFκB and Kidney Injury.

Authors:  Ning Song; Friedrich Thaiss; Linlin Guo
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

Review 7.  Podocyte Injury in Lupus Nephritis.

Authors:  Hamza Sakhi; Anissa Moktefi; Khedidja Bouachi; Vincent Audard; Carole Hénique; Philippe Remy; Mario Ollero; Khalil El Karoui
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

8.  The proteases HtrA2/Omi and UCH-L1 regulate TNF-induced necroptosis.

Authors:  Justyna Sosna; Susann Voigt; Sabine Mathieu; Dieter Kabelitz; Ahmad Trad; Ottmar Janssen; Catherine Meyer-Schwesinger; Stefan Schütze; Dieter Adam
Journal:  Cell Commun Signal       Date:  2013-10-03       Impact factor: 5.712

9.  Wnt/β-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy.

Authors:  Hongxia Zhang; Weili Luo; Yonghong Sun; Yanchun Qiao; Liying Zhang; Zhilian Zhao; Shijun Lv
Journal:  Int J Mol Sci       Date:  2016-08-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.